UCB stock holds support as 2025 sales rise

UCB (BE0003739530) stock is anchored by reported 2025 sales of EUR 6.1 billion and adjusted EBITDA of EUR 1.7 billion, with free cash flow of EUR 1.2 billion in the same year. Those figures frame the shares as investors weigh a larger earnings base against the companys current market valuation.

2025 revenue base

UCB reported EUR 6.1 billion in revenue for 2025, up from EUR 5.3 billion in 2024, which is a year-on-year increase of roughly 15%. The company also reported adjusted EBITDA of EUR 1.7 billion in 2025, compared with EUR 1.4 billion a year earlier.

That combination matters because the margin profile improved alongside growth. Free cash flow reached EUR 1.2 billion in 2025, after EUR 0.9 billion in 2024, showing a second consecutive step up in cash generation.

Cash and profit mix

Net profit attributable to shareholders reached EUR 789 million in 2025, versus EUR 634 million in 2024. UCB also said research and development expenses totaled EUR 1.0 billion in 2025, underscoring how much of the business is still tied to pipeline investment.

The balance between higher profit and heavy R&D spend is the key read-through for investors. A larger cash buffer can support launches, while the income statement shows the cost of sustaining that pipeline.

Investor materials stay current

UCBs investor relations page remained the main company reference point on 16 July 2026, and the latest corporate reporting cadence still centers on the 2025 annual numbers. The reported revenue gain of about 15% is the cleanest comparison in the set and gives the stock a measurable fundamental anchor.

For market readers, the important question is less about the business model itself than about whether the 2025 earnings base can hold through 2026. The reported jump in cash flow and EBITDA gives the company more room, but it also raises the bar for the next update.

Briviact and launch mix

Briviact remains one of UCBs representative products, and the drug is part of the broader neurology portfolio that supports recurring sales. Product concentration matters because a limited number of therapies can move revenue faster than a broad consumer mix.

In 2025, that portfolio helped UCB deliver EUR 6.1 billion in revenue and EUR 1.7 billion in adjusted EBITDA, which is why the product mix remains a central driver for the stock.

Valuation focus

UCB stock is best read through the combination of growth, cash generation, and research intensity. The 2025 figures show EUR 6.1 billion in revenue, EUR 1.7 billion in adjusted EBITDA, and EUR 1.2 billion in free cash flow, all from the same reporting year.

Those numbers are the core reference points for the shares as of 16 July 2026, even without a fresh price print in the available data. The companys latest reported fundamentals still define the trading case.